Join
Live feed
·
PRReleasevia Quantisnow
Citius Oncology Inc. logo
Citius Pharmaceuticals Inc. logo

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

ByQuantisnow·Wall Street's wire, on your screen.
CTOR· Citius Oncology Inc.CTXR· Citius Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTOR (Citius Oncology Inc.), CTXR (Citius Pharmaceuticals Inc.) and more on Quantisnow.